About

Labomed is a privately owned service provider (Contract Development and Manufacturing Organization) focused on Pharma services of added-value generic products for oral liquid dosage forms. Our brand new, purpose-built Liquids Center is supported by an in-house QC laboratory, robust quality systems and a team of specialists with high caliber credentials in the development, manufacturing and commercialization of pharmaceutical products. It’s this combination of expertise and infrastructure that makes Labomed your preferred partner for product development and manufacturing utilizing controlled substances. We Offer licensing rights and optimized supply agreements for differentiated, tailor-made added value generic products. Amongst other, a proprietary pain management portfolio addressing moderate to severe pain is available as unique presentations and drug combinations.

Solution & Product

Labomed has already accumulated significant know-how, intellectual property and projects intended for commercialization via out-licensing and supply models. The company provides the below services that differentiate its products against existing generics, by providing at the same solutions to any problems that will occur: a) Drug repurposing (re-development strategies) b) Drug reformulation c) Drug re-profiling (usage of known drugs for new diseases, new indications etc.) d) Drug repositioning find a non-yet exploited or used values of the existing medicinal product) e) having its own state of the art manufacturing and testing facility (designed flexibly and customizable for small and medium scale batches).

Innovation & Scalability

Our competitive advantage is what we like to call ourselves: “One stop shop”. We offer contract development, testing and manufacturing, starting from API evaluation, analytical, formulation, process optimization, and registration up to EU-GMP tasks during all stages of product lifecycle management. We additionally provide consulting services which can benefit our clients by giving the multiple insights throughout the industry. We can provide the whole spectrum of services from the concept to the final product, which blended with our high experienced and high expertise people, differentiates us from any other company in Europe. Labomed exploits the need for “turn-key” R&D / CDMO services to mid-sized pharma companies that : (i) cannot afford the development and maintenance of a fully-fledged R&D lab and registration back office and/or (ii) focus primarily on the distribution side of the business and, hence, lack productive capacity for specialized batches. This is an extremely expandable niche market with pan-European footprint (and substantial growth potential in the U.S.), serviced by just a handful of companies. We offer our customers a complete package combining product development (initial feasibility study, API selection, pre-formulation analysis and formulation trials, prototype and scaled-up production batches, model production and tests, clinical and in vitro analyses, filing of dossiers , issuance of market authorization etc.) and manufacturing services.

Traction & achievements

Labomed has managed in the short-term of 5 years to have accumulated significant know-how, Intellectual property rights and projects intended for commercialization in EU and US, by working either on Co-Development projects or on its Own Developments. Having 16 patent applications to EPO& PCT, 13 products approved & launched in UK (time record) and other EU markets, 5 products to be submitted and other in Pipeline (R&D phase), we are proud to have a Niche portfolio available for Licensing and Supply deals. Specifically, Labomed has already submitted six European applications, three US applications and 7 GR applications for its unique products and presentations. Labomed has established long-term business cooperation models with successful international pharmaceutical companies (e.g. Helm AG and Adalvo), which a significant proof of our company's specialty and professionalism.

Team & Why Us

Senior Management team and Heads of R&D pair more than 25 years of expertise in pharmaceutical development to assess, identify and help potential customers discover added value opportunities. Labomed is operated by Senior Pharma Executives and supported by a Board of Advisors, who provide significant industry experience as well as access to extensive network of experts and key opinion leaders on pharmaceutical industry and healthcare business in general. Αs of June 2022, the company employs 61 highly educated, technically trained staff. The CEO and major shareholder has been the manager of five pharmaceutical companies and offers the benefit of experience in this complex, regulated industry. The plant director has a remarkable academic qualification in the field and more than 20 active years with hands-on experience in product development and manufacturing (global presence).

Funding Needs

Being in a capital intensive industry makes continuous funding a "must-have" in order to achieve future growth. Both in terms of manufacturing capacity as well as R&D services.